B. Metzler seel. Sohn & Co. AG Grows Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• B. Metzler seel. Sohn & Co. AG increased its holdings in Bristol Myers Squibb by 103.1%, acquiring an additional 81,276 shares in the first quarter, bringing their total ownership to 160,075 shares valued at $9.76 million.
• Major Wall Street brokerages have adjusted their ratings, with Citigroup lowering its target price to $47 and assigning a "neutral" rating, indicating potential caution among investors.
• Bristol Myers Squibb recently announced a quarterly dividend of $0.62, representing an annual yield of 5.2%, despite a high payout ratio of 100% and a modest revenue increase compared to the previous year.

B. Metzler seel. Sohn & Co. AG boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 103.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 160,075 shares of the biopharmaceutical company's stock after buying an additional 81,276 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Bristol Myers Squibb were worth $9,763,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of BMY. Wellington Management Group LLP raised its position in Bristol Myers Squibb by 297.0% in the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after buying an additional 17,750,938 shares during the last quarter. Ameriprise Financial Inc. raised its position in Bristol Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after buying an additional 12,011,983 shares during the last quarter. GQG Partners LLC raised its position in Bristol Myers Squibb by 22,647.6% in the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock worth $733,310,000 after buying an additional 11,970,598 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Bristol Myers Squibb by 701.2% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after buying an additional 10,913,708 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at about $624,369,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

BMY stock traded up $0.29 during midday trading on Friday, hitting $47.17. The company's stock had a trading volume of 10,685,502 shares, compared to its average volume of 10,735,505. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The firm has a market capitalization of $96.01 billion, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 2.41 and a beta of 0.36. The company has a 50 day moving average of $47.05 and a two-hundred day moving average of $50.74.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the prior year, the company posted $2.07 EPS. The firm's revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Analysts Set New Price Targets

BMY has been the topic of several recent research reports. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup dropped their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.